Bethany Sensenig
Direttore/Membro del Consiglio presso SUPERNUS PHARMACEUTICALS, INC.
Patrimonio netto: - $ in data 31/03/2024
Posizioni attive di Bethany Sensenig
Società | Posizione | Inizio | Fine |
---|---|---|---|
SUPERNUS PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 21/08/2023 | - |
Independent Dir/Board Member | 21/08/2023 | - | |
Naia Rare Diseases LLC
Naia Rare Diseases LLC Medical/Nursing ServicesHealth Services Naia Rare Diseases, Inc. develops pharmaceutical drugs for Short Bowel Syndrome (SBS) and other rare gastrointestinal diseases. The firm offers NB 1001 for adult SBS, NB 1001 for pediatric SBS, and NB 1002, a GLP-2 agonist. The company was founded by H. Daniel Perez and Mark Bagnall in 2014 and is headquartered in Cayman Islands. | Amministratore Delegato | - | - |
Direttore Finanziario/CFO | - | - |
Storia della carriera di Bethany Sensenig
Precedenti posizioni note di Bethany Sensenig
Società | Posizione | Inizio | Fine |
---|---|---|---|
9 METERS BIOPHARMA, INC. | Amministratore Delegato | 26/05/2023 | 17/07/2023 |
Direttore Finanziario/CFO | 18/01/2022 | 17/07/2023 | |
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | Direttore Finanziario/CFO | 01/03/2019 | 01/01/2022 |
BIOGEN INC. | Corporate Officer/Principal | 01/04/2006 | 01/03/2019 |
Formazione di Bethany Sensenig
Montreat College | Undergraduate Degree |
Western Carolina University | Masters Business Admin |
Statistiche
Distribuzione geografica
Stati Uniti | 7 |
Israele | 2 |
Posizioni
Director of Finance/CFO | 3 |
Chief Executive Officer | 2 |
Undergraduate Degree | 1 |
Settori
Health Technology | 5 |
Consumer Services | 3 |
Health Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
BIOGEN INC. | Health Technology |
SUPERNUS PHARMACEUTICALS, INC. | Health Technology |
9 METERS BIOPHARMA, INC. | Health Technology |
Aziende private | 2 |
---|---|
Minovia Therapeutics Ltd.
Minovia Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Minovia Therapeutics Ltd. is a clinical stage company based in Tirat Carmel, Israel. Minovia Therapeutics is developing a therapeutic platform called mitochondrial augmentation technology (mat) that targets the root cause of diseases generated by mitochondrial dysfunction. The platform enriches patients' hematopoietic stem and progenitor cells with healthy mitochondria isolated from an allogeneic or syngeneic source. The Israeli company's initial clinical focus is on rare mitochondrial diseases for which there are no approved treatments, and the lead product, mnv-201, is composed of autologous hematopoietic stem cells enriched with healthy allogeneic mitochondria. Minovia Therapeutics completed an ind enabled phase i/ii clinical trial in Pearson syndrome, a fatal pediatric disease, and is planning to accelerate the clinical development for Pearson syndrome and expand the pipeline to other hematological/mitochondrial-related diseases. The company was founded in 2012 by Natalie Yivgi-Ohana, Uriel Halavee, Ephraim Aharonson, and Natalie Yivgi-Ohana has been the CEO since 2012. | Health Technology |
Naia Rare Diseases LLC
Naia Rare Diseases LLC Medical/Nursing ServicesHealth Services Naia Rare Diseases, Inc. develops pharmaceutical drugs for Short Bowel Syndrome (SBS) and other rare gastrointestinal diseases. The firm offers NB 1001 for adult SBS, NB 1001 for pediatric SBS, and NB 1002, a GLP-2 agonist. The company was founded by H. Daniel Perez and Mark Bagnall in 2014 and is headquartered in Cayman Islands. | Health Services |
- Borsa valori
- Insiders
- Bethany Sensenig
- Esperienza